These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 18652859)

  • 1. Monoamine oxidase inactivation: from pathophysiology to therapeutics.
    Bortolato M; Chen K; Shih JC
    Adv Drug Deliv Rev; 2008; 60(13-14):1527-33. PubMed ID: 18652859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Focusing on new monoamine oxidase inhibitors.
    Bolasco A; Carradori S; Fioravanti R
    Expert Opin Ther Pat; 2010 Jul; 20(7):909-39. PubMed ID: 20553094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review.
    Manzoor S; Hoda N
    Eur J Med Chem; 2020 Nov; 206():112787. PubMed ID: 32942081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advancements and SAR Studies of Synthetic Coumarins as MAO-B Inhibitors: An Updated Review.
    Kaur P; Rangra NK
    Mini Rev Med Chem; 2024; 24(20):1834-1846. PubMed ID: 38778598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The state of the art of pyrazole derivatives as monoamine oxidase inhibitors and antidepressant/anticonvulsant agents.
    Secci D; Bolasco A; Chimenti P; Carradori S
    Curr Med Chem; 2011; 18(33):5114-44. PubMed ID: 22050759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches.
    Duarte P; Cuadrado A; León R
    Handb Exp Pharmacol; 2021; 264():229-259. PubMed ID: 32852645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells.
    Nagatsu T; Sawada M
    J Neural Transm Suppl; 2006; (71):53-65. PubMed ID: 17447416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Monoamine oxidase as a target for drug action].
    Drozak J; Kozłowski M
    Postepy Hig Med Dosw (Online); 2006; 60():498-515. PubMed ID: 17060892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.
    Naoi M; Riederer P; Maruyama W
    J Neural Transm (Vienna); 2016 Feb; 123(2):91-106. PubMed ID: 25604428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging role of monoamine oxidase as a therapeutic target for cardiovascular disease.
    Deshwal S; Di Sante M; Di Lisa F; Kaludercic N
    Curr Opin Pharmacol; 2017 Apr; 33():64-69. PubMed ID: 28528298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.
    Youdim MB; Bakhle YS
    Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S287-96. PubMed ID: 16402116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAO-A and -B gene knock-out mice exhibit distinctly different behavior.
    Shih JC; Chen K
    Neurobiology (Bp); 1999; 7(2):235-46. PubMed ID: 10591056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs related to monoamine oxidase activity.
    Fišar Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Aug; 69():112-24. PubMed ID: 26944656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme Inhibition Assays for Monoamine Oxidase.
    Mathew B; Oh JM; Parambi DGT; Sudevan ST; Kumar S; Kim H
    Methods Mol Biol; 2024; 2761():329-336. PubMed ID: 38427248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting Monoamine Oxidase in CNS and CVS would be a Promising Approach to Mitigating Cardiovascular Complications in Neurodegenerative Disorders.
    Srivastava P; Sudevan ST; Thennavan A; Mathew B; Kanthlal SK
    CNS Neurol Disord Drug Targets; 2024; 23(3):331-341. PubMed ID: 36872357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Structure-Activity Relationship (QSAR) Studies for the Inhibition of MAOs.
    Ramesh M; Muthuraman A
    Comb Chem High Throughput Screen; 2020; 23(9):887-897. PubMed ID: 32208114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patent-related survey on new monoamine oxidase inhibitors and their therapeutic potential.
    Carradori S; Secci D; Bolasco A; Chimenti P; D'Ascenzio M
    Expert Opin Ther Pat; 2012 Jul; 22(7):759-801. PubMed ID: 22702491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoamine oxidases in development.
    Wang CC; Billett E; Borchert A; Kuhn H; Ufer C
    Cell Mol Life Sci; 2013 Feb; 70(4):599-630. PubMed ID: 22782111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A second life for MAO inhibitors? From CNS diseases to anticancer therapy.
    Sblano S; Boccarelli A; Mesiti F; Purgatorio R; de Candia M; Catto M; Altomare CD
    Eur J Med Chem; 2024 Mar; 267():116180. PubMed ID: 38290352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.